Interesting results from the exploratory biomarker analysis of KN-522 study
Heidi Ko, Medical Director of Medical Affairs at Labcorp Drug Development, reshared a post on LinkedIn by Amol Akhade, Senior Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, adding:
“Really interesting results from the exploratory biomarker analysis of KN-522 study, indeed.
Several immune-related biomarkers, HRD status, TNBC molecular subtypes, and metabolic pathway signatures were:
Prognostic for outcomes (pCR and/or EFS), but Predictive of benefit from pembrolizumab.”
Quoting Amol Akhade ‘s post:
“Can we find out some biomarkers which are predictive of response for pembrolizumab in Keynote 522 ?
Interesting sub set analysis.
Note the definition of high TMB .
More or less expected results.”
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital.
He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant.
More posts featuring Heidi Ko and Amol Akhade.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023